Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori.

Abstract:

AIM:To identify optimal antibiotics for second-line quadruple therapy of Helicobacter pylori after failed 1-week triple therapy. METHODS:One hundred patients were enrolled in this study after the failure of 1-week triple therapy. They were randomized to receive 1-week quadruple therapy consisting of amoxicillin, omeprazole and bismuth salts, plus either metronidazole or tetracycline. Before quadruple therapy, the H. pylori culture of each patient was tested for metronidazole resistance or clarithromycin resistance by E-test. Six weeks later, an endoscopy or 13C-urea breath test was used to define the success of H. pylori eradication. RESULTS:The H. pylori eradication rates by intention-to-treat and per protocol analysis were higher in the tetracycline group than in the metronidazole group (intention-to-treat: 78% vs. 58%, P < 0.05; per protocol: 89% vs. 67%, P < 0.05). In the metronidazole group, but not in the tetracycline group, the per protocol eradication rate of quadruple therapy was lower for the infected isolates with metronidazole resistance than for those without metronidazole resistance (77% vs. 33%, P < 0.05). CONCLUSION:Quadruple therapy, including tetracycline and amoxicillin, improves the H. pylori eradication rate after failed triple therapy.

journal_name

Aliment Pharmacol Ther

authors

Chi CH,Lin CY,Sheu BS,Yang HB,Huang AH,Wu JJ

doi

10.1046/j.1365-2036.2003.01653.x

subject

Has Abstract

pub_date

2003-08-01 00:00:00

pages

347-53

issue

3

eissn

0269-2813

issn

1365-2036

pii

1653

journal_volume

18

pub_type

临床试验,杂志文章,随机对照试验
  • Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.

    abstract:BACKGROUND:Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM:To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS:A r...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14016

    authors: Ma C,Fedorak RN,Kaplan GG,Dieleman LA,Devlin SM,Stern N,Kroeker KI,Seow CH,Leung Y,Novak KL,Halloran BP,Huang VW,Wong K,Blustein PK,Ghosh S,Panaccione R

    更新日期:2017-05-01 00:00:00

  • The prevalence of Helicobacter pylori in peptic ulcer disease.

    abstract::Both duodenal and gastric ulcer disease are closely associated with Helicobacter pylori infection. An infected individual has an estimated lifetime risk of 10-20% for the development of peptic ulcer disease, which is at least 3-4 fold higher than in non-infected subjects. H. pylori infection can be diagnosed in 90-100...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Kuipers EJ,Thijs JC,Festen HP

    更新日期:1995-01-01 00:00:00

  • Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Clostridium difficile (C. difficile) infection in hospitals in developed countries continues to be a major public health hazard despite increased control measures including review of antibiotic policies and hygiene measures. Patients with colitis are thought to be particularly vulnerable to C. difficile asso...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04661.x

    authors: Jen MH,Saxena S,Bottle A,Aylin P,Pollok RC

    更新日期:2011-06-01 00:00:00

  • Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.

    abstract::In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o.m. and 91 cimetidine 800 mg nocte for 2 or, if then not healed, 4 weeks. After 2 weeks the healing rates on an intention-to-treat basis were: for omeprazole 62% and for cimetidine 33% (P less than 0.001), an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00193.x

    authors: Crowe JP,Wilkinson SP,Bate CM,Willoughby CP,Peers EM,Richardson PD

    更新日期:1989-02-01 00:00:00

  • Prevalence of coeliac disease in Northwest China: heterogeneity across Northern Silk road ethnic populations.

    abstract:BACKGROUND:Epidemiological data of coeliac disease are lacking from the central Asian region. AIMS:To verify the occurrence of coeliac disease amongst four major ethnic groups of Xinjiang Uyghur Autonomus Region, China. METHODS:2277 in-patients with gastrointestinal symptoms (1391 Han, 608 Uyghur, 146 Kazakh and 132 ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15737

    authors: Zhou C,Gao F,Gao J,Yuan J,Lu J,Sun Z,Xu M,Engel J,Hui W,Gilissen L,Chen H

    更新日期:2020-06-01 00:00:00

  • Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

    abstract:BACKGROUND:Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia. AIM:To assess utility of these markers in a Western population. METHODS:SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prev...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14471

    authors: Song M,Camargo MC,Weinstein SJ,Murphy G,Freedman ND,Koshiol J,Stolzenberg-Solomon RZ,Abnet CC,Männistö S,Albanes D,Rabkin CS

    更新日期:2018-02-01 00:00:00

  • Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.

    abstract:BACKGROUND:The efficacy of interferon-alpha plus ribavirin treatment for patients not responding to interferon monotherapy is not well established. AIM:To assess the efficacy and safety of combination therapy with interferon-alpha 2a/2b plus ribavirin by performing a meta-analysis of randomized clinical trials. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1046/j.1365-2036.2002.01328.x

    authors: San Miguel R,Guillén F,Cabasés JM,Buti M

    更新日期:2002-09-01 00:00:00

  • Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

    abstract::The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00488.x

    authors: Rashid MU,Bateman DN

    更新日期:1990-08-01 00:00:00

  • Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.

    abstract:BACKGROUND:The accuracy of symptom-based diagnostic criteria for irritable bowel syndrome (IBS) is modest. AIMS:To derive and validate a new test that utilises latent class analysis. METHODS:Symptom, colonoscopy, and histology data were collected from 1981 patients and 360 patients in two cohorts referred to secondar...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13949

    authors: Sood R,Gracie DJ,Gold MJ,To N,Pinto-Sanchez MI,Bercik P,Moayyedi P,Ford AC,Law GR

    更新日期:2017-03-01 00:00:00

  • Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.

    abstract:BACKGROUND:Orlistat reduces energy uptake by the impairment of fat digestion and some evidence indicates it also lowers plasma cholesterol. AIM:To examine total, low-density lipoprotein- and high-density lipoprotein cholesterol during a weight reducing regimen, and assess the effect of orlistat in lowering cholesterol...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.01966.x

    authors: Erdmann J,Lippl F,Klose G,Schusdziarra V

    更新日期:2004-06-01 00:00:00

  • Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

    abstract:BACKGROUND:The widespread use of eradication therapy for Helicobacter pylori in Japan has led to an increase in antibiotic-resistant strains and the problem of re-treatment in cases of eradication failure. AIM:To perform drug sensitivity testing for metronidazole in 92 H. pylori-positive patients who had failed eradic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01401.x

    authors: Murakami K,Sato R,Okimoto T,Nasu M,Fujioka T,Kodama M,Kagawa J

    更新日期:2003-01-01 00:00:00

  • Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test.

    abstract::Assessment of intragastric urease activity by the 13C-urea breath test was performed before and after one day of dosing with either De-Noltabs (tripotassium dicitrato bismuthate, one tablet 1 q.d.s.), Pepto-Bismol liquid (bismuth salicylate 30 ml q.d.s.), or Roter tablets (bismuth subnitrate, one tablet q.d.s.) in twe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1992.tb00549.x

    authors: Prewett EJ,Luk YW,Fraser AG,Lam WM,Pounder RE

    更新日期:1992-02-01 00:00:00

  • Review: clinical trials in peptic ulcer disease--problems of methodology and interpretation.

    abstract::This review focuses on the methodology and interpretation of drug trials in peptic ulcer disease. The problems of planning and conduct that are discussed include the ethics of using placebo, eligibility criteria, estimations of sample size, stopping rules, randomization, blinding, and efficacy criteria, that is, ulcer...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1987.tb00610.x

    authors: Lauritsen K,Rask-Madsen J

    更新日期:1987-04-01 00:00:00

  • Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding.

    abstract:BACKGROUND:Re-bleeding of Helicobacter pylori-associated peptic ulcer disease is reduced by H. pylori eradication. AIM:To validate a non-invasive test, the Premium Platinum HpSA stool test, in patients with upper gastrointestinal bleeding. METHODS:Stool samples of consecutive patients with relevant bleeding from gast...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01548.x

    authors: Peitz U,Leodolter A,Kahl S,Agha-Amiri K,Wex T,Wolle K,Günther T,Steinbrink B,Malfertheiner P

    更新日期:2003-04-01 00:00:00

  • Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.

    abstract:BACKGROUND:Liver biopsy is the gold standard in evaluating liver diseases but is susceptible to complications. Safety data on aspiration needle biopsies remain limited. AIM:To evaluate the safety of percutaneous liver biopsy performed with Klatskin needle. METHODS:Clinical and biochemical data were retrospectively re...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13939

    authors: Takyar V,Etzion O,Heller T,Kleiner DE,Rotman Y,Ghany MG,Fryzek N,Williams VH,Rivera E,Auh S,Liang TJ,Hoofnagle JH,Koh C

    更新日期:2017-03-01 00:00:00

  • Analysis of the cag pathogenicity island and IS605 of Helicobacter pylori strains isolated from patients with gastric cancer in Japan.

    abstract:BACKGROUND:CagA protein is encoded by the cagA gene, which is part of the cag pathogenicity island (PAI) in Helicobacter pylori. Insertion sequence (IS) elements are a diverse set of specialized DNA segments that can move to new sites in bacterial genomes. AIM:To determine the role of cagPAI and IS605 in the developme...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01982.x

    authors: Deguchi R,Igarashi M,Watanabe K,Takagi A

    更新日期:2004-07-01 00:00:00

  • Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.

    abstract:BACKGROUND:Liver transplantation (LT) offers a possible cure for carefully selected patients with hepatocellular carcinoma (HCC). Studies report that preoperative alpha-fetoprotein (AFP) is a prognostic indicator that can predict survival and recurrence in these patients. AIM:To undertake a systematic review of availa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05060.x

    authors: Hakeem AR,Young RS,Marangoni G,Lodge JP,Prasad KR

    更新日期:2012-05-01 00:00:00

  • Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret.

    abstract:BACKGROUND:In patients with primary sclerosing cholangitis follow-up magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is performed by many centres, particularly for the early detection of biliary malignancies and strictures. Clinically meaningful MRI-based definitions of primary ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14797

    authors: Zenouzi R,Liwinski T,Yamamura J,Weiler-Normann C,Sebode M,Keller S,Lohse AW,Schramm C,International PSC Study Group (IPSCSG).

    更新日期:2018-07-01 00:00:00

  • Review article: the treatment of fatty liver disease associated with the metabolic syndrome.

    abstract::The treatment of non-alcoholic fatty liver disease may be worthwhile to prevent progression to advanced liver failure, but no therapy is definitely evidence-based. Weight loss or lifestyle modifications remain the primary line of intervention, particularly in overweight or obese subjects. In adult non-alcoholic fatty ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2005.02593.x

    authors: Marchesini G,Natale S,Manini R,Agostini F

    更新日期:2005-11-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract:BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12908

    authors: Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期:2014-10-01 00:00:00

  • Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.

    abstract:BACKGROUND:Proton pump inhibitors (PPI) are widely used to treat acid-related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI-associated adverse events. In recent years, data from next-generation sequencing studies suggested that PPIs affect the composi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15604

    authors: Macke L,Schulz C,Koletzko L,Malfertheiner P

    更新日期:2020-03-01 00:00:00

  • Review article: Immunosuppressants in distal ulcerative colitis.

    abstract:BACKGROUND:Distal ulcerative colitis may prove to be resistant to steroids and aminosalicylates, but total colectomy is more difficult to justify than in severe extensive colitis. Immunosuppression is of established benefit in generalized colitis, but there are no data available specific to distal disease. AIM:To dete...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01170.x

    authors: Falasco G,Zinicola R,Forbes A

    更新日期:2002-02-01 00:00:00

  • Histamine receptor antagonists and incident colorectal adenomas.

    abstract:BACKGROUND:Prior studies suggest that histamines may modulate the development of colorectal neoplasia. AIM:To assess whether histamine receptor antagonist use was associated with adenoma formation. METHODS:Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy wit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2005.02529.x

    authors: Robertson DJ,Burke CA,Schwender BJ,Wargovich MJ,Greenberg ER,Sandler RS,Ahnen DJ,Rothstein R,Mott LA,Baron JA

    更新日期:2005-07-15 00:00:00

  • Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

    abstract:BACKGROUND:The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. AIM:To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantag...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2003.01462.x

    authors: Caprilli R,Cottone M,Tonelli F,Sturniolo G,Castiglione F,Annese V,Papi C,Viscido A,Cammà C,Corrao G,Latella G

    更新日期:2003-02-15 00:00:00

  • Childhood coeliac disease: towards an improved serological mass screening strategy.

    abstract:BACKGROUND:In 1997-1998, 6127 asymptomatic children aged 2-4 years were screened for coeliac disease (CD) by anti-endomysium (EmA) testing in the Netherlands. After 6 (+/-2) months, biopsies were performed in 57 seropositive children; 31(54%) had villous atrophy, but 26 (46%), all HLA-DQ2/DQ8 positive, had normal histo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.04226.x

    authors: Hogen Esch CE,Csizmadia GD,van Hoogstraten IM,Schreurs MW,Mearin ML,von Blomberg BM

    更新日期:2010-04-01 00:00:00

  • Review article: visceral hypersensitivity.

    abstract::Visceral hypersensitivity is highly prevalent in all functional bowel disorders. Most also demonstrate wider patterns of somatic referral of intestinal pain or discomfort. This hypersensitivity may explain the symptoms as the sensitive gut can be more easily provoked by normal or abnormal motor events in the gut. Visc...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01447.x

    authors: Mertz H

    更新日期:2003-03-01 00:00:00

  • Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.

    abstract:OBJECTIVE:To compare the efficacy of proton pump inhibitor vs. ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori eradication. METHODS:Randomized trials comparing 1-week regimens with (i) proton pump inhibitor plus two antibiotics [clarithromycin (C) and amoxycillin (A) or a nitroi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.2000.00809.x

    authors: Gisbert JP,González L,Calvet X,Roqué M,Gabriel R,Pajares JM

    更新日期:2000-09-01 00:00:00

  • Review article: safety of bismuth in the treatment of gastrointestinal diseases.

    abstract::Bismuth preparations are commonly used to treat a variety of gastrointestinal disorders, including peptic ulcers and dyspepsia. The safety profile of currently approved bismuth preparations, such as tripotassium dicitrato bismuthate (De-Nol), bismuth subsalicylate (Pepto-Bismol) and ranitidine bismuth citrate (Pylorid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1996.22163000.x

    authors: Tillman LA,Drake FM,Dixon JS,Wood JR

    更新日期:1996-08-01 00:00:00

  • Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers.

    abstract:AIM:To determine whether misoprostol promotes the healing of non-steroidal anti-inflammatory drug-induced gastroduodenal lesions in a human experimental model. METHODS:Mucosal damage and healing of mucosal biopsy sites were assessed endoscopically in 10 healthy, Helicobacter pylori-negative volunteers with a normal in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1996.29171000.x

    authors: Dorta G,Nicolet M,Vouillamoz D,Margalith D,Blum AL,Armstrong D,Saraga E

    更新日期:1996-08-01 00:00:00

  • Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis.

    abstract:BACKGROUND:Several clinical trials evaluating the prophylactic effect of allopurinol on postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis have been published; however, there is no consensus on whether prophylactic allopurinol can reduce the incidence of post-ERCP pancreatitis. AIM:To compare proph...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2008.03756.x

    authors: Bai Y,Gao J,Zhang W,Zou D,Li Z

    更新日期:2008-09-01 00:00:00